Steven Kao

1.2k total citations
18 papers, 454 citations indexed

About

Steven Kao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Steven Kao has authored 18 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 3 papers in Biotechnology. Recurrent topics in Steven Kao's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Occupational and environmental lung diseases (5 papers). Steven Kao is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Occupational and environmental lung diseases (5 papers). Steven Kao collaborates with scholars based in Australia, United States and Japan. Steven Kao's co-authors include Benjamin Solomon, Benjamin Besse, Rita Chiari, Todd M. Bauer, Antonello Abbattista, Alice T. Shaw, Holger Thurm, Jean‐François Martini, Gerson Peltz and Gregory J. Riely and has published in prestigious journals such as The Lancet Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Steven Kao

17 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Kao Australia 6 395 266 107 67 26 18 454
M. D’Arcangelo Italy 12 196 0.5× 200 0.8× 119 1.1× 79 1.2× 11 0.4× 31 360
Vanessa Chaire France 11 171 0.4× 181 0.7× 137 1.3× 55 0.8× 13 0.5× 19 315
Santiago Ponce-Aix Spain 11 233 0.6× 199 0.7× 159 1.5× 59 0.9× 36 1.4× 17 425
Lucile Armenoult France 7 208 0.5× 73 0.3× 88 0.8× 83 1.2× 29 1.1× 9 314
Eric D. Mininberg United States 3 307 0.8× 345 1.3× 192 1.8× 96 1.4× 9 0.3× 6 494
Bastianina Canu Italy 10 103 0.3× 197 0.7× 136 1.3× 84 1.3× 18 0.7× 15 346
Vibha Raghavan Canada 8 125 0.3× 228 0.9× 171 1.6× 109 1.6× 37 1.4× 12 399
Xinmin Yu China 11 252 0.6× 239 0.9× 93 0.9× 46 0.7× 9 0.3× 24 382
Α. Kotsakis Greece 11 147 0.4× 223 0.8× 132 1.2× 53 0.8× 30 1.2× 23 338
Satoshi Taga Japan 10 251 0.6× 191 0.7× 217 2.0× 113 1.7× 47 1.8× 18 514

Countries citing papers authored by Steven Kao

Since Specialization
Citations

This map shows the geographic impact of Steven Kao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Kao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Kao more than expected).

Fields of papers citing papers by Steven Kao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Kao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Kao. The network helps show where Steven Kao may publish in the future.

Co-authorship network of co-authors of Steven Kao

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Kao. A scholar is included among the top collaborators of Steven Kao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Kao. Steven Kao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zhuang, Ling, Kenneth Lee, Sonja Klebe, et al.. (2025). A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma. Journal of Experimental & Clinical Cancer Research. 44(1). 51–51. 3 indexed citations
2.
Singhal, Nimit, et al.. (2024). Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report. Journal of Thoracic Oncology. 19(4). 650–652. 3 indexed citations
3.
4.
Kao, Steven, Veronica Cheung, Wendy A. Cooper, et al.. (2024). Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. Molecular Oncology. 19(7). 1998–2013. 3 indexed citations
5.
Pal, Abhijit, Adnan Nagrial, Jenny Lee, et al.. (2023). Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. 20(1). 16–24. 4 indexed citations
6.
7.
Cho, Byoung Chul, W. Marston Linehan, D. Ross Camidge, et al.. (2022). Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 174. S1–S2. 13 indexed citations
8.
Itchins, Malinda, Hannah C. Ainsworth, Marliese Alexander, et al.. (2022). A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. Clinical Lung Cancer. 23(8). 702–708. 3 indexed citations
9.
Itchins, Malinda, Shuang Liang, T. Barnes, et al.. (2021). P24.03 Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial. Journal of Thoracic Oncology. 16(10). S1030–S1032. 2 indexed citations
10.
Kao, Steven, et al.. (2021). The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia‐Pacific Region. Asia-Pacific Journal of Clinical Oncology. 18(3). 177–190.
11.
Peters, Solange, Alice T. Shaw, Benjamin Besse, et al.. (2020). Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 144. 10–19. 15 indexed citations
12.
Nowak, Anna K., W. Joost Lesterhuis, Peey‐Sei Kok, et al.. (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology. 21(9). 1213–1223. 115 indexed citations
13.
Shaw, Alice T., Benjamin Solomon, Rita Chiari, et al.. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 20(12). 1691–1701. 248 indexed citations
14.
Mahar, Annabelle, et al.. (2019). P1.09-26 Prevalence of PD-L1 Expression Rates in Different NSCLC Specimens. Journal of Thoracic Oncology. 14(10). S506–S506. 7 indexed citations
15.
16.
Nowak, Anna K., Peey‐Sei Kok, W. Joost Lesterhuis, et al.. (2018). OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result. Journal of Thoracic Oncology. 13(10). S338–S339. 25 indexed citations
17.
Kirschner, Michaela B., et al.. (2013). MC13-0031 Tumour miR-210 expression is elevated in malignant pleural mesothelioma patients with shorter survival undergoing extrapleural pneumonectomy. European Journal of Cancer. 49. S20–S20. 1 indexed citations
18.
Kirschner, Michaela B., Yuen Yee Cheng, Steven Kao, et al.. (2012). Increased circulating miR-625-3p. Murdoch Research Repository (Murdoch University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Vanessa Chaire Breakdown of academic impact, for papers by Santiago Ponce-Aix Breakdown of academic impact, for papers by Lucile Armenoult Breakdown of academic impact, for papers by Eric D. Mininberg Breakdown of academic impact, for papers by Bastianina Canu Breakdown of academic impact, for papers by Vibha Raghavan Breakdown of academic impact, for papers by Xinmin Yu Breakdown of academic impact, for papers by Α. Kotsakis Breakdown of academic impact, for papers by Satoshi Taga
Rankless by CCL
2026